December 2012 | Volume 11 | Issue 12 | Features | 1521 | Copyright © December 2012
Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This department may include additional information from the manufacturers, plus reports from physicians who wish to share their clinical experience with these new products. In addition, we will inform our readers about the latest drugs receiving Food and Drug Administration (FDA) approval.
Star Scientific's Rock Creek Pharmaceuticals, Inc,
Star Scientific, Inc's subsidiary Rock Creek Pharmaceuticals,
Inc, has announced that its new Anatabloc® face cream is now
available on the cosmetic portion of the Anatabloc Web site
(www.anatabloc.com) and in select dermatology practices.
The product is a formulation of anatabine citrate-one of the
active ingredients in the Anatabloc nutritional supplement-
and a botanically based emollient. Rock Creek touts the cream's
ability to improve the appearance of the skin based on the results
of a case series conducted by dermatologist Dr. Susan H.
Weinkle of Bradenton, FL, president of the American Society for
Dermatologic Surgery and assistant clinical professor of Dermatology
at the University of South Florida.
Sanofi, Coca-Cola Join Efforts on Beauty Drinks
Sanofi and Coca-Cola are working together to produce and market
a line of drinks called Beautific Oenobiol, which they claim
will improve skin, strengthen hair, and increase vitality. The
drinks are made with mineral water, fruit juice, and nutritional
ingredients. The drink lines will include a hair-and-fingernail
strengthener, a weight-loss aid, a vitality booster, and a skin aid.
Pliaglis Receives FDA Approval as Topical
Nuvo Research has announced that the FDA has approved a
supplemental New Drug Application for a 7% lidocaine/7% tetracaine
cream as a topical local anesthetic to minimize pain
during dermatologic procedures.
Pliaglis 7%/7% Cream is designed to form a pliable peel on the
skin when exposed to air. It is indicated for use on intact adult
skin to provide local analgesia for superficial aesthetic procedures,
including dermal filler injection, pulsed dye laser therapy,
facial laser resurfacing, and laser-assisted tattoo removal.
In clinical studies, the most common reactions to Pliaglis were erythema (47%), skin discoloration (16%), and edema
(14%); all were generally mild and resolved soon after
treatment, according to the news release. Adverse events
included headache, vomiting, dizziness, and fever, all occurring
less than 1% of the time.
LEO Pharma Inc Receives FDA Approval for Taclonex
Taclonex Topical Suspension is a once-daily, steroid-containing treatment combining vitamin D analog (calcipotriene) and a corticosteroid (betamethasone dipropionate) for use up to 8
weeks. The first-line, single treatment requires only one prescription for both scalp and body treatment of plaque psoriasis. Patients using Taclonex Topical Suspension may also be eligible to participate in a patient support program.
Two phase 3 clinical studies included more than 1,600 patients with scalp psoriasis, and one phase 3 study involved more than 1,100 patients with body plaque psoriasis, with a higher percentage of
patients treated with Taclonex achieving disease control compared with patients using monotherapies or vehicle alone, according to
the release. Folliculitis and burning sensation of the skin were the
most common adverse reactions in at least 1% of subjects treated
with Taclonex, a rate higher than in vehicle-treated participants.
Taclonex Topical Suspension is the only once-daily, steroidcontaining
topical treatment that combines the strength and
benefits of 2 active ingredients, a vitamin D analog (calcipotriene)
and a corticosteroid (betamethasone dipropionate).
FDA Approves Alma Lasers' Skin Resurfacing Module
Alma Lasers has annouced that it received FDA clearance for its
new fractionated skin resurfacing module, the Pixel RF.
The Pixel RF uses "InMotion Refractive Radiofrequency Micro
Plasma Technology," which ablates and heats the skin through
controlled, focused delivery of energy without using disposables,
according to a company news release.
According to the company, the technology causes evaporation, mechanical
damage, and thermal damage below the epidermis, which
provides significant dermal impact, but minimal epidermal disruption,
and can be used on all skin types. The company further states
that the fractionated resurfacing with radiofrequency technology
does not harm the skin's outer layer, resulting in healing time that
is faster than traditional CO2 lasers. Alma Lasers said monthly treatments
typically deliver optimal results in 2 to 3 months.